This research, published in The Lancet, explores the benefits of adding a short course of chemotherapy before standard chemoradiotherapy for women with locally advanced cervical cancer. The INTERLACE trial, an international, multicentre, randomised phase 3 trial, compared the standard treatment with a group that received induction chemotherapy followed by the standard chemoradiotherapy. The study found that induction chemotherapy significantly improved both progression-free survival and overall survival in patients with locally advanced cervical cancer. While the treatment caused increased haematological toxicity, particularly neutropenia, the benefits were considered clinically meaningful, and the researchers recommend that this treatment approach be included in clinical guidelines as an option to improve outcomes in patients with locally advanced cervical cancer.

Research paper:

Click here to read the research paper

Voiced by NotebookLM

Disclaimer